Partners

Scientific Strategy

At Repron Therapeutics we are developing first-in-class epigenetic silencers for repressing the transcriptional network of the most cancerous oncogenes. We have developed an innovative strategy to inhibit the activity of oncogenes at the basis of tumor malignancy through the usage of engineered synthetic factors.

Selected Publication

A SOX2-engineered epigenetic silencer factor represses the glioblastoma genetic program and restrains tumor development - Science Advances - 2022

info@reprontherapeutics.com

bottom of page